替吉奥单药治疗晚期胃癌的近期疗效及安全性评价

Evaluation of the short-term efficacy and safety of TS-1 in treatment of advanced gastric cancer

目的探讨替吉奥单药或联合最佳支持治疗用于晚期胃癌治疗的疗效与不良反应。方法对符合入组条件的胃癌患者采用替吉奥每日80mg/m2,分二次在早晚饭后半小时用水吞服。连续2周停1周,3周重复。结果 48例患者共接受195周期替吉奥单药化疗,完全缓解(CR)0例,部分缓解(PR)21例(43.8%),稳定(SD)24例(50.0%),治疗总有效率(RR)43.8%。主要不良反应为消化道反应,骨髓抑制。结论替吉奥单药治疗晚期胃癌疗效较好,不良反应轻而且安全,是治疗晚期胃癌,特别是年龄较大、一般状态较差的患者的安全有效的治疗方案。

Objective To evaluate the efficacy and adverse effect of TS-1 in treatment of advanced gastric cancer.Methods All enrolled patients received TS-1 orally at a dose of 80 mg/m2 daily divided into 2 doses administered half an hour after breakfast and supper.The treatment lasted 2 weeks,followed by 1-week interval.The protocal was repeated every 3 weeks.Results Of the 48 patients with advanced gastric cancer,21 could not be operated due to distant metastasis,27 had recurrent tumor after operation.All patients received a total of 195 cycles of chemotherapy.There were 0 CR,21 PR and 24 SD,with a response rate（RR） of 43.8%.The major toxic reactions were hematological and digestive toxic reactions.Conclusion TS-1 single-drug regimen achieved relatively satisfactory short-term efficacy in the treatment of advanced gastric cancer with mild adverse effects and good tolerance.It is safe and effective for patients with advanced gastric cancer,especially for old patients.